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ABSTRACT
The accumulation of Ab (amyloid b-protein) is one of the
major pathological hallmarks in AD (Alzheimer’s disease).
Gangliosides, sialic acid-containing glycosphingolipids
enriched in the nervous system and frequently used as
biomarkers associated with the biochemical pathology of
neurologicaldisorders, havebeensuggestedtobeinvolvedin
the initial aggregation of Ab. In the present study, we have
examined ganglioside metabolism in the brain of a double-
Tg(transgenic)mousemodelofADthatco-expressesmouse/
human chimaeric APP (amyloid precursor protein) with the
Swedishmutationandhumanpresenilin-1witha deletionof
exon 9. Although accumulation of Ab was confirmed in the
double-Tg mouse brains and sera, no statistically significant
change was detected in the concentration and composition
of major ganglio-N-tetraosyl-series gangliosides in the
double-Tg brain. Most interestingly, Chol-1a antigens
(cholinergic neuron-specific gangliosides), such as GT1aa
and GQ1ba, whichare minorspeciesin thebrain, were found
to be increased in the double-Tg mouse brain. We interpret
that the occurrence of these gangliosides may represent
evidence for generation of cholinergic neurons in the AD
brain, as a result of compensatory neurogenesis activated by
the presence of Ab.
Key words: Alzheimer’s disease, amyloid b-peptide, Chol-1a
antigen, cholinergic neuron, ganglioside, transgenic mouse.
INTRODUCTION
AD (Alzheimer’s disease) is a progressive degenerative disease
of the brain. It is the most common form of dementia and is
characterized clinically by progressive loss of cognitive
functions such as memory and learning and eventual death.
Neuronal loss and brain atrophy are major hallmarks of AD,
particularly in the basal forebrain cholinergic nuclei and their
targets in the cortex and hippocampus. Neuropathologically,
AD is characterized by the occurrence of amyloid deposits
or ‘senile plaques’ in the brain, which consist mainly of an
aggregated variant of Ab (amyloid b-protein) (Ariga et al.,
2008). Ab undergoes a conformational transition from ran-
dom coil to ordered structure rich in b-sheets and fibrils
(Selkoe, 2002). Thus, although earlier views were that
the appearance of Ab is a marker of disease progression,
accumulating evidence has indicated that they actually play a
role in the neurodegenerative process (Yankner and Lu, 2009).
Among the many possible mechanisms, there have been
reports indicating that Ab may become ‘seeds’ for the
formation of fibrils after the addition of lipid vesicles
containing GM1 (Yanagisawa, 2007).
Gangliosides are sialic acid-containing glycosphingolipids
expressed primarily in the outer leaflet of the plasma mem-
brane of all vertebrate cells and are particularly abundant
in neurons of the nervous system (Yu, 1994). Several earlier
studies showed changes of ganglioside expression in AD
brain. For example, ganglioside levels decreased in most of
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asnneuro.org / Volume 2 (4) / art:e00044 233the brain regions, including the cerebral cortex, hippocam-
pus, and basal telencephalon, and especially in the frontal
cortex and white matter (Crino et al., 1989; Svennerholm
and Gottfries, 1994). Svennerholm and Gottfries (1994)
reported that the concentration of gangliosides was
reduced to 58–70% of the control level in all four grey
matter areas and to 81% in frontal white matter of AD type
I (early-onset or familial) cases, whereas it was only
significantly reduced in temporal cortex, hippocampus,
and frontal white matter in AD type II (late-onset or
sporadic) cases. Clearly, the reduced ganglioside levels are
correlated with the severe loss of neurons in the affected
brain. The major brain ganglio-N-tetraosyl-series ganglio-
side species (GT1b, GD1b, GD1a and GM1) are significantly
decreased in the frontal and temporal cortices and basal
telencephalon of the brains of patients with AD compared
with the respective areas in control brains (Kracun et al.,
1990; Kracun et al., 1992). Brooksbank and McGovern
(1989) and Crino et al. (1989) also reported changes of
ganglioside composition in AD brains in which
b-series gangliosides, such as GT1b and GD1b, showed a
significant decrease, in contrast with a slight increase in
GT1a, GD3, GM1 and GM2. Since gangliosides have a strong
affinity for Ab (Ariga et al., 2001), they could possibly
participate in conformational changes of Ab (Choo-Smith
et al., 1997). For this reason, ganglioside metabolism has
been considered to be closely associated with the
pathogenesis of AD (Mutoh et al., 2006; Ariga et al., 2008).
To further examine whether this association is present
in animal models of AD whose pathology is well defined, we
investigated the ganglioside composition of the brain in a
double-Tg (transgenic) mouse model of AD that co-expresses
mouse/human chimaeric APP (amyloid precursor protein)
with Swedish double-mutation (K595N/M596L) (APPswe)
and human PSEN1dE9 [PSEN-1 (presenilin-1) with a deletion
of exon 9], and compared it with that of age-matched
WT (wild-type) controls. Since their introduction two
decades ago (Hsiao et al., 1996; Hsiao, 1998), AD model
mice overexpressing APP have been proven to be useful in
testing hypotheses of AD pathogenesis and testing rational
therapeutic strategies. On the other hand, these Tg models
overexpressing human APP only develop a partial AD-like
phenotype and only recapitulate certain features of human
AD. Pathologically they show amyloid plaque deposits,
elevated Ab levels, neuritic changes, phosphorylated tau
protein epitopes, a-synuclein-positive neuritis, gliotic reac-
tions and inflammatory responses (for a review, see Turner,
2001). It is also interesting to note that cholinergic
abnormalities exist in the immediate vicinity of amyloid
plaques of these mutants (Sturchler-Pierrat et al., 1997;
Wong et al., 1999). Given the salience of neuropathology in
the cholinergic pathways mediating cognition in AD and the
relative lack of information about ganglioside concentrations
in these areas, we made additional efforts to examine
gangliosides that may serve as biomarkers of cholinergic
neurons in the present paper.
MATERIALS AND METHODS
Materials and animals
Authentic Chol-1a gangliosides, GT1aa and GQ1ba, were
isolated from bovine brains (Ando et al., 1992; Hirabayashi
et al., 1992). The double-Tg mouse model of AD [B6.Cg-Tg
(APPswe,PSEN1dE9)85Dbo/J] co-expressing APPswe and
PSEN1dE9 (Jankowsky et al., 2001; Jankowsky et al., 2004)
was purchased from JAX Mice and Services (Bar Harbor, ME,
U.S.A.). Double-Tg and age-matched WT mice were maintained
for 1 year according to the guidelines of the Institutional
Animal Care and Use Committee of the Medical College of
Georgia. Genotypes of mice were confirmed by PCR of genomic
DNAs using specific primer sets for APPswe, PSEN1dE9 and
mouse prion protein promoter. For serum preparation, blood
samples were collected immediately by heart puncture after
mice were anaesthetized. Mice were then killed by cervical
dislocation, and the brains were quickly removed. The middle
third of brains was sliced using a brain matrix (Braintree
Scientific, Braintree, MA, U.S.A.) to prepare brain slices for
immunohistochemical and biochemical analyses. For ganglio-
side analysis, the brain slices were stored at 280˚C until use.
Immunohistochemistry of Abs in brain sections
Coronal sections (12 mm thick) were prepared from brain slices
using a cryostat and were mounted on frost-free glass slides. Each
section was pretreated with 1% BSA in PBS for 15 min to block
non-specific binding and then incubated with biotinylated
monoclonal antibody against human Ab (clone 82E1; IBL-
America, Minneapolis, MN, U.S.A.; 1:100 in 1% BSA in PBS)
overnight at 4˚C. The 82E1 antibody detects soluble and fibrillar
Ab1–42 and Ab1–40. After washing with PBS, the section was
incubated in 1% BSA in PBS containing rhodamine-conjugated
anti-mouse IgG antibody for 2 h, followed by nuclear staining
with Hoechst 33258 (Sigma–Aldrich, St. Louis, MO, U.S.A.) for
10 min. The slide was mounted and covered with a coverslip. The
section was then examined using a fluorescence microscope.
Quantification of Ab1–42 in sera
The concentrations of serum Ab1–42 in double-Tg and age-
matched WT mice were determined using a Human b Amyloid
(1-42) ELISA kit, High-Sensitive (Wako Chemicals USA,
Richmond, VA, U.S.A.). In brief, 100 ml of serum, prepared
from blood samples by centrifugation (10000 rev./min for
10 min) and diluted to an appropriate titre in PBS, was placed
into a well of a 96-well microtitre plate coated with anti-
human Ab1–16 antibody and then incubated at 4˚C overnight.
After washing with a wash solution, the sample was
incubated for 1 h in 100 ml of horseradish peroxide-
conjugated anti-human Ab35–43 antibody (Fab9 fragment).
The sandwiched Ab1–42 was visualized with a TMB (3,39,5,59-
tetramethylbenzidine) solution and the absorbance was
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reader after the addition of a stop solution.
Ganglioside isolation and HPTLC (high-
performance TLC)
Gangliosides were isolated from brain slices containing
hippocampal/cortical tissue (150–210 mg wet weight) of
double-Tg and age-matched WT mice as previously described
(Ariga et al., 1988). In brief, total lipids were extracted
sequentially with 5 ml each of chloroform/methanol (1:2, 1:1
and 2:1, by volume) and chloroform/methanol/water
(30:60:8, by volume; solvent A). The combined lipid extracts
were evaporated and redissolved in 5 ml of solvent A and
applied to a diethylaminoethyl-Sephadex A-25 column
(acetate form, 2 ml bed volume), followed by elution with
20 ml of solvent A to remove neutral lipids. The acidic lipids,
including gangliosides, were then eluted with 20 ml of
chloroform/methanol/0.8 M sodium acetate in water
(30:60:8, by volume), followed by desalting using Sep-Pak
Cartridge column chromatography (Waters, Milford, MA,
U.S.A.; Kubo and Hoshi, 1985). Lipid-bound sialic acid
contents in the acidic lipid fraction were determined by the
resorcinol/hydrochloric acid reagent (Svennerholm, 1957). A
portion of the acidic lipid fraction, containing a ganglioside
sample with 5 mg of sialic acid, was applied to an HPTLC plate
and developed with chloroform/methanol/0.2% calcium
chloride in water (50:45:10, by volume). After development,
gangliosides on HPTLC plates were visualized by spraying the
orcinol/sulfuric acid reagent and heating at 100˚C and then
quantified by densitometric analysis. Statistical comparison
of the data was performed by the Student’s t test.
HPTLC immunostaining
HPTLC immunostaining was performed as previously
described (Ngamukote et al., 2007). After developing the
HPTLC plate as described above, the plate was coated with an
n-hexane solution containing 0.4% polyisobutylmethacrylate
(polymer; Sigma–Aldrich) for 1 min. After drying, the plate
was incubated for 2 h at room temperature with an anti-
Chol-1a monoclonal antibody (GGR-41; IgG; Kusunoki et al.,
1993) diluted with 1% BSA in PBS. The plate was then
incubated for 1 h with horseradish peroxide-conjugated anti-
mouse IgG secondary antibody (Jackson ImmunoResearch
Laboratories, West Grove, PA, U.S.A.) diluted with 1% BSA in
PBS. Bands recognized by the antibody were detected using
the Western Lightening Western Blot Chemiluminescence
reagent (PerkinElmer Life and Analytical Sciences, Boston,
MA, U.S.A.). Chol-1a antigens were quantified by densito-
metric analysis. After the plate was dipped in chloroform to
remove excess polymer, ganglioside bands were visualized by
spraying orcinol/sulfuric acid reagent and heating at 100˚C.
RESULTS
Immunohistochemical detection of Ab in double-
Tg mouse brains
First, we confirmed whether our double-Tg mice co-
expressing APPswe and PSEN1dE9 represent a valid model
of the plaque formation in AD. Figure 1 shows immuno-
histochemical localization of Ab in the cortex of AD double-
Tg mice. It has been reported that these double-Tg mice
develop substantial Ab deposits in their brains by 6 months of
age (Jankowsky et al., 2004). Consistently, the appearance
of Ab staining (shown in red) was massive and mostly in the
cortical region of the brains of 1-year-old double-Tg mice,
and was confined to the extracellular areas, except in the
cerebral vessels where it lined the vessel wall (Figure 1). There
were no gender-related differences in the immunostaining
(results not shown), consistent with the notion that Ab
deposits in the brain are a general pathological hallmark in
AD (Selkoe, 2002). As expected, the WT mice did not show any
evidence of Ab staining (results not shown).
Concentration of Ab1–42 in double-Tg mouse
sera
Figure 2 shows the concentrations of serum Ab1–42 in double-
Tg and age-matched WT mice determined by ELISA using anti-
Ab1–16 antibody and anti-Ab1–42 antibody. The Ab1–42 level
Figure 1 Immunohistochemical localization of Ab in the cortex of
double-Tg mice co-expressing APPswe and PSEN1dE9
The coronal brain sections are 12 mm thick. Nuclei (blue) and Ab (red) were
stained with Hoechst 33258 and anti-human Ab antibody respectively. (a)
Low-magnification view; (b) high-magnification view. Scale bar: (a)2 0mm
and (b)5mm.
Expression of Chol-1a antigens in AD mouse brains
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235was significantly highin sera ofdouble-Tg mice, butnotinsera
of WT mice. In human AD, elevated levels of serum Ab were
reported to be associated with vascular risk factors of AD
(Sundelof et al., 2008; Abdullah et al., 2009). Longitudinal
evaluations ofserumAb shouldprovidea betterunderstanding
ofthesignificanceofthisassociationinADaetiology(Abdullah
et al., 2009). Using these double-Tg mice as a model of AD, we
then evaluated the metabolism of brain gangliosides.
Composition of major gangliosides in double-Tg
mouse brains
In human AD, several earlier studies documented abnormal
ganglioside metabolism in brain regions of demented patients, in
which the ganglioside levels were significantly reduced (Crino
et al., 1989; Svennerholm and Gottfries, 1994). In addition,
analysis of the ratios of a- and b-series gangliosides revealed that
b-series gangliosides were preferentially decreased in brain
regions of demented AD patients (Crino et al., 1989).
The decreased levels of gangliosides are consistent with the
degradation of cortical neurons, especially in the frontal cortex
(Kalanj et al., 1991), and a reduced density of nerve endings in
the brain regions of demented AD patients (Svennerholm and
Gottfries, 1994). Hence, these findings suggest that abnormal
ganglioside metabolism coincides with the affected cortical areas
of neurodegeneration that afflicts AD.
In contrast with these human studies, we found no
significant differences in the lipid-bound sialic acid content
in the brain slices containing hippocampal/cortical tissue
prepared from double-Tg and age-matched WT mice
(Table 1). In addition, there was no significant difference in
the expression levels of major ganglio-N-tetraosyl ganglio-
sides (GM1, GD1a, GD1b and GT1b) in the brains between
double-Tg and age-matched WT mice (Figure 3a and Table 1).
This is consistent with the report by Sawamura et al. (2000)
who also did not detect notable changes in major ganglioside
patterns in the brains of mutant PSEN-2 double-Tg mice
despite the remarkable increase in the level of Ab1–42 and
significantly lower levels of glycerophospholipids and sphin-
gomyelin. In addition, Bernardo et al. (2009) did not find
significant differences in a- or b-series gangliosides between
WT and double-Tg mice expressing APPswe and PSEN1dE9.
These studies as well as our present results indicate no
significant changes in major brain ganglioside metabolism in
AD model mice, despite the presence of massive accumulation
of Ab deposits in the brains of these animals.
Composition of minor gangliosides in double-Tg
mouse brains
Several investigators have documented alteration of minor
gangliosides in human AD. Kracun et al. (1990) and Kalanj
et al. (1991) reported that the levels of simple gangliosides,
such as GM2 and GM3, were elevated in the frontal and
parietal cortices in AD brains; the elevation of GM2 and GM3 in
these areas may correlate with an accelerated lysosomal
degradation of gangliosides occurring during neuronal death
and astrogliosis respectively. Barrier et al. (2007) also
reported an increase in GM2 and GM3 within the cortices of
Tg mice expressing human APP751 with Swedish and London
mutations and human PSEN-1 (M146L). In the present study,
GM3 was slightly increased in double-Tg mouse brains
compared with WT mouse brains (Table 1); the increase was
statistically significant for GM3 in female double-Tg mouse
brains. We attribute the small and significantly elevated GM3
to the gliotic reactions or invading macrophages that occur
more prominently in female Tg mice than in the males. We
did not find any significant difference in the content of GM2
between double-Tg and WT mouse brains (Table 1).
Increase of Chol-1a antigens (GT1aa andGQ1ba)
in double-Tg mouse brains
The most consistent and interesting finding of the present
study, however, is the increased expression of Chol-1a
antigens, GT1aa and GQ1ba, in the brain of double-Tg mice
(Figures 3b and 4). These gangliosides are normally minor
species in the brain and serve as markers of cholinergic
neurons (Ando et al., 1992; Hirabayashi et al., 1992). The
expression of Chol-1a antigens in rat brain regions such as
the hippocampus is developmentally regulated, and their
concentrations increase with aging (Derrington and Borroni,
1990). Chol-1a antigens are first detected between days 10
and 20 of postnatal age, reaching adult levels on day 50 in
normal rat brains (Derrington et al., 1990). In the present
study, we found that the expression levels of Chol-1a
antigens, especially GQ1ba, were elevated in double-Tg
mouse brains as compared with those in WT mouse brains
(Figures 3b and 4). The increase was especially significant in
female double-Tg mouse brains. No significant differences
were found in the expression of GT1aa and GQ1ba between
male and female WT mouse brains. These observations may
reflect a change in specific ganglioside metabolism associated
with the pathological processes underlying AD.
Figure 2 Serum Ab1–42 concentration in double-Tg and age-matched
WT mice
Serum Ab1–42 concentrations were quantified using a Human b Amyloid
(1–42) ELISA kit, High-Sensitive (Wako Chemicals USA); n53–4.
T. Ariga and others
236 E 2010 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.DISCUSSION
In this study, we examined ganglioside metabolism in the
brains of double-Tg mice expressing APPswe and PSEN1dE9, a
model of amyloid aggregation and associated neuropathology
of AD. No statistically significant change in major brain
gangliosides was detected, as reported previously (Sawamura
et al., 2000). Among minor brain gangliosides, however, the
expression of GM3 exhibited a slight increase in the female
double-Tg mouse brains. Most importantly, an increase in the
cholinergic neuron-specific gangliosides, GT1aa and GQ1ba,
also known as Chol-1a antigens, was found in the double-Tg
mouse brains. In AD patient sera, the presence of antibodies
Table 1 Lipid-bound NeuAc contents in gangliosides in double-Tg and age-matched WT mouse brains (mean¡S.D.; n53–7)
Ganglioside
WT Tg
Male Female Male Female
Expressed in terms of a percentage
GM3 1.3¡0.1 1.0¡0.4 1.6¡0.3 3.1¡0.3*
GM2 0.6¡0.1 0.6¡0.3 0.9¡0.3 1.0¡0.4
GM1 19.8¡0.5 18.3¡1.1 18.0¡2.0 20.3¡0.9
GD3 1.3¡0.2 0.9¡0.4 0.7¡0.3 0.8¡0.4
GD1a 28.3¡0.4 32.2¡1.4 26.5¡1.6 30.4¡0.6
GD2 2.7¡0.4 2.6¡0.8 1.9¡0.4 1.7¡0.5
GT1a 1.7¡0.1 1.6¡0.4 1.5¡0.2 1.8¡0.5
GD1b 17.0¡0.1 15.4¡1.4 18.0¡0.7 14.6¡0.5
GT1b 24.0¡0.4 23.3¡0.8 26.2¡1.1 23.0¡1.3
GQ1b 3.2¡0.2 3.8¡0.9 4.0¡0.8 3.3¡0.8
Expressed in terms of mg/g of
wet weight
NeuAc 341.9¡35.4 347.3¡60.7 340.7¡33.5 344.2¡11.0
* P,0.05.
Figure 3 Expression of gangliosides in double-Tg and age-matched WT mouse brains
Lanes 1–3, male WT mouse brain gangliosides; lanes 4–6, female WT mouse brain gangliosides; lanes 7–11, male double-Tg mouse
brain gangliosides; lanes 12–14, female double-Tg mouse brain gangliosides; lane 15, authentic GT1aa (4 ng) and GQ1ba (20 ng).
Gangliosides were separated by HPTLC with a solvent system of chloroform/methanol/0.2% CaCl2 (55:45:10, by volume) and
visualized by (a) orcinol/sulfuric acid staining or (b) immunostaining with an anti-Chol-1a monoclonal antibody (GGR-41).
Expression of Chol-1a antigens in AD mouse brains
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237that bind specifically to cholinergic neurons has been
reported (Chapman et al., 1988). The increase in these
antibodies in the patients may be attributed to the increase in
Chol-1a antigens in AD brains found in the study. As
discussed below, it is possible that these Chol-1a antigens are
involved in the aetiology of AD by preferentially affecting
cholinergic neurons.
Chol-1a antigens are marker glycolipids of mature choli-
nergic terminals (Richardson et al., 1982; Derrington and
Borroni, 1990). These antigens are expressed relatively late
during the maturation process of the cholinergic synapse in rat
brains (Derrington and Borroni, 1990). In vitro, their expression
levels were found to be significantly higher in the rat
hippocampus and septum slices treated with nerve growth
factor, which stimulates the maintenance of cholinergic
neurons (Derrington et al., 1990; Gahwiler et al., 1990).
Consistent with these reports, Chol-1 antigens were found to
co-localizewith cholineacetyltransferase in thehumancentral
nervous system (Whittaker et al., 1992). In addition, Chol-1a
antigens have been suggested to play functional roles in
cholinergic neurons. For instance, it has been reported that
treatment with anti-Chol-1a monoclonal antibody inhibited
the release of acetylcholine from synaptosomes prepared from
rat brains (Ando et al., 2004). Also, administration of the anti-
Chol-1a antibody to rats markably suppressed the memory and
learning abilities. On the other hand, treatment with Chol-1a
antigens induced choline uptake by synaptosomes; as a result
of increased choline uptake, acetylcholine synthesis was
enhanced. These findings indicate that Chol-1a antigens can
ameliorate decreased functions of synapses in aged brains,
suggesting that Chol-1a antigens play a pivotal role in
cholinergic synaptic transmission and participate in cognitive
functions (Ando et al., 1998). Presynaptic degenerative
changes in basal forebrain cholinergic nuclei have been
observed in AD brain. Similarly, Ab1–42 has been suggested to
inducethedeathofbasalforebraincholinergicneuronsinmice
via p75 neurotrophin receptor (Sotthibundhu et al., 2008). It
was expected that up-regulation of Chol-1a antigens in
cholinergic neurons represents evidence of a compensatory
mechanism for the decline of cholinergic function in the AD
model mouse brains. This interpretation is particularly relevant
in light of the fact that there islittleif any neurodegeneration in
the double-Tg mouse.
On the other hand, there also is a possibility that Chol-1a
antigens are involved in neurogenesis in AD brains. Although
the occurrence of neurogenesis in brains in human AD
patients is still controversial (Waldau and Shetty, 2008), a
growing body of evidence has accumulated indicating an
increase of adult neurogenesis not only in APP-overexpres-
sing mouse model brains, but also in AD patient brains (Jin
et al., 2004b, 2004a; Lopez-Toledano and Shelanski, 2004). It
has been consistently reported that Ab is capable of
stimulating the proliferation of neural stem cells and adult
neurogenesis (Lopez-Toledano and Shelanski, 2004;
Sotthibundhu et al., 2009). In contrast, other studies have
suggested that Ab has cytotoxic effects on neural stem cells
and disrupts neurogenesis (Haughey et al., 2002a, 2002b;
Millet et al., 2005). It has also been reported that Ab1–40 and
GM1 co-operatively induce cell death in mouse neural stem
cells (Yanagisawa et al., 2010). These reports clearly suggest
neurogenic or neurotoxic effects of Ab in neurogenesis in AD
brains, which needs to be resolved. In light of our finding that
there is an increase in the level of Chol-1a antigens in the Tg-
model animals, it is tempting to suggest that the increase is
associated with neurogenesis. Although we have no direct
evidence of this association, Chol-1a antigens, GT1aa and
GQ1ba, have been reported to be expressed in mouse neural
stem cells (Ngamukote et al., 2007). This report can be taken
as indirect evidence that Chol-1a antigens are involved in
neurogenesis. Further, neurogenesis may also be involved
in the compensatory mechanism for the decline of choliner-
gic function in AD brains as discussed above. There is the
intriguing possibility that degeneration of the cholinergic
pathways in early stages of the disease could result in a
rebound of neurogenesis at later stages of the disease, which
is expected to be reflected by the appearance of Chol-1a
antigens in the brain. If this possibility were true, it would
open a window of opportunity for the treatment of the
disease by promoting neurogenesis. We fully realize that
increased neurogenesis alone is not sufficient to produce
new, functional neurons. It would be important, therefore, to
Figure 4 The content of Chol-1a antigens, GT1aa (a) and GQ1ba (b), in
double-Tg and age-matched WT mouse brains
GT1aa and GQ1ba were quantified by densitometric analysis of HPTLC
immunostaining; n53–8. Statistical analyses were performed by the
Student’s t test. For GT1aa, P,0.01 (Tg male compared with WT male);
P,0.04 (Tg female compared with WT female); P,0.05 (Tg male compared
with Tg female) respectively. For GQ1ba, P,0.03 (Tg male compared with WT
male); P,0.02 (Tg female compared with WT female); P,0.02 (Tg male
compared with Tg female) respectively.
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properly into the hippocampal formation. In this regard, the
discovery of adult neurogenesis raises the possibility that
the nervous system has an intrinsic capacity for repair.
Perhaps more controversially, it raises the question as to
whether impaired or failed neurogenesis may contribute
to the decline in neurodegenerative diseases (Abdipranoto
et al., 2008). Future studies are clearly needed to examine
whether it is possible to promote neurogenesis to achieve
functional recovery in AD.
I nt h ep r e s e n ts t u d y ,t h ei n c r e a s ei nC h o l - 1 a was
significantly higher in female double-Tg mice. It has been
generally recognized that the prevalence of AD is also higher
in women. However, the aetiology of high risk of AD in
women is unknown. A role for oestrogen, by influencing brain
development (pre- or post-menarche) or senescence (post-
menopause), is a leading hypothesis. Some studies suggest a
protective effect of oestrogen replacement therapy in the risk
of developing AD (Turner, 2001). In addition to the preva-
lence of AD, virtually all cholinergic characteristics have been
reported to be affected by sex differences. Berger-Sweeney
(2003) has reported that sexual dimorphism in the develop-
ment of the cholinergic basal forebrain system could have
significant consequences for cognitive performance in sex
differences during development and aging. In normal
animals, basal acetylcholine concentrations, high-affinity
choline uptake and choline acetyltransferase activity are
different between females and males (Rhodes and Rubin,
1999). Cholinergic areas, such as amygdala and hippocampus,
are larger in male than those in female (Madeira and
Lieberman, 1995). Oestrogen, which may be involved in the
high prevalence of AD in women, can modulate neurogenesis,
differentiation, growth and survival of neurons in develop-
ment and throughout the life of animals (Tanapat et al., 1999;
Schaevitz and Berger-Sweeney, 2005). In fact, it has been
reported that female mice have more proliferative cells in
dentate gyrus than male mice in an oestrogen-level-
dependent manner (Tanapat et al., 1999). It is expected that
the increase in Chol-1a gangliosides in female double-Tg
mice compared with male double-Tg mice is attributable to
neurogenesis and the increase in cholinergic neurons in the
high levels of oestrogen. The intriguing possibility that a
higher neurogenesis occurs in female Tg mice certainly merits
further experimentation.
Finally, AD model animals with disrupted ganglioside
biosynthesis have also been used to examine the relationship
between ganglioside metabolism and aspects of AD. For
example, Bernardo et al. (2009) analysed the AD model of Tg
mice expressing APPswe and PSEN1dE9 crossbred with mice
deficient in GD3-synthase, which catalyses the synthesis of
b-series gangliosides. In the triple mutant mice, b-series
gangliosides, including GD3, were completely absent, but GM1
and GD1a were significantly increased by 63.8% and 50.8%
respectively. On the other hand, Oikawa et al. (2009) crossbred
Tg mice expressing human APP having Swedish and London
mutations with GM2-synthase-knockout mice in which GM1,
GD1a, GD1b and GT1b were completely missing but GM3 and
GD3 were abundantly expressed (Takamiya et al., 1996). The
mutant mice expressing no GM1 showed a significant increase
of Ab accumulation in vascular tissues and formation of
dysphonic-form amyloid angiopathy in the brain. These results
suggest that b-series gangliosides derived from GD3-synthase
could contribute to Ab accumulation in the brain of these
mutants. Indeed, Ariga et al. (2001) showed a strong
correlation between the number of sialic acid residues on a
ganglioside and its affinity for Ab. In this model system the
more complex b-series gangliosides had higher affinity for Ab
than the a-series gangliosides. Thus inhibition of GD3-synthase
can be a novel therapeutic target to combat the cognitive
deficits, amyloid plaque formation and neurodegeneration
seen in AD. Targeting GD3-synthase would also have the effect
of reducing levels of GQ1ba and GT1aa. It would be interesting
to examine how this pattern of changes affects neurogenesis,
AD-related neuropathology and cognitive functions.
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